Figure 3.
MK-0616-PCSK9 (proprotein convertase subtilisin/kexin type 9) complex. A, Interaction of PCSK9 catalytic domain and prodomain with the LDLR epidermal growth factor and β-propeller domains, respectively, from PDB ID: 3P5B.21 B, Modeling MK-0616 from related crystal structures (PDB IDs: 6XID, 6XIE, 75SG, and 75SH)18,20 suggests MK-0616 (deep teal) interacts with a flat surface on the PCSK9 catalytic domain (pink surface), interrupting the interaction with the EGF(A) domain (transparent yellow) of LDLR. Compound 35 (PDB ID: 7S5H), a closely related analog of Compound 44,18,20 is shown in white sticks, overlaid with MK-0616 to illustrate the binding site similarity. C, MK-0616 and Compound 3518,20 can form key hydrogen bonds with T377, F379, and S381 of PCSK9-Cat domain. Cpd 35 indicates Compound 35; EGF, epidermal growth factor; LDLR-EGF, LDL receptor-EGF; PCSK9-Cat, PCSK9-catalytic doman; PCSK9-CTD, PCSK9-C-terminal domain; Phe 379, phenylalanine 379; Ser 381, serine 381; and Thr 377, threonine 377.